Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 1
2009 1
2010 3
2011 3
2012 5
2013 8
2014 7
2015 11
2016 14
2017 15
2018 9
2019 10
2020 13
2021 7
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23898127

102 results

Results by year

Filters applied: . Clear all
Page 1
Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.
Iliakis T, Papadopoulou V, Diamantopoulos PT, Panayiotidis P, Zervakis K, Giannakopoulou N, Tilimidos G, Angelopoulou M, Siakantaris MP, Pangalis G, Mantzourani M, Variami E, Viniou NA. Iliakis T, et al. Anticancer Res. 2013 Aug;33(8):3509-14. Anticancer Res. 2013. PMID: 23898127
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Shiseki M, et al. Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26. Int J Clin Oncol. 2017. PMID: 28550414 Free PMC article. Clinical Trial.
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, Abraham I. Yun S, et al. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27101984 Review.
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Hess G, et al. J Clin Oncol. 2005 Oct 20;23(30):7583-93. doi: 10.1200/JCO.2005.01.3110. J Clin Oncol. 2005. PMID: 16234522 Clinical Trial.
102 results